LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience.

    Goedhals, Louis / Falkson, Geoffrey / Smith, Brenda Lynn / Falkson, Carla Isadora / Gasmi, Jamal / Lategan, Andries / Burillon, Jean-Philippe / His, Patricia

    Anticancer research

    2005  Volume 25, Issue 3c, Page(s) 2489–2492

    Abstract: Background: This phase II trial was performed to assess the activity and safety of the cisplatin and vinorelbine combination in patients with advanced cervical carcinoma.: Patients and methods: Forty-two patients with advanced cervical cancer were ... ...

    Abstract Background: This phase II trial was performed to assess the activity and safety of the cisplatin and vinorelbine combination in patients with advanced cervical carcinoma.
    Patients and methods: Forty-two patients with advanced cervical cancer were included in the study to receive vinorelbine at 30 mg/m2 on d 1 and d 8 and cisplatin 100 mg/m2 on day 1 every 4 weeks.
    Results: Thirty-seven patients were evaluable for response and 40 patients for tolerance. Twenty-four patients (64.8%) achieved objective responses. The median duration of response was 17.5 months (range 2.5-57 months), median time to progression was 13.2 months (range 0.4-57 months) and median survival was 20.6 months (range 0.4-55 months). This regimen was well-tolerated; no WHO grade 4 neutropenia was observed, grade 3 nausea and vomiting occured in 50% of patients and grade 2 peripheral neuropathy in 5% of patients.
    Conclusion: Vinorelbine-cisplatin is an active and well-tolerated regimen in advanced cervical carcinoma.
    MeSH term(s) Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/pathology ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Middle Aged ; Neoplasm Staging ; Uterine Cervical Neoplasms/drug therapy ; Uterine Cervical Neoplasms/pathology ; Vinblastine/administration & dosage ; Vinblastine/adverse effects ; Vinblastine/analogs & derivatives
    Chemical Substances Vinblastine (5V9KLZ54CY) ; Cisplatin (Q20Q21Q62J) ; vinorelbine (Q6C979R91Y)
    Language English
    Publishing date 2005-05
    Publishing country Greece
    Document type Clinical Trial ; Clinical Trial, Phase II ; Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Guidelines for CPD accreditation of the South African Society of Medical Oncology.

    Abratt, Raymond P / Eek, Richard W / Eele, Richard / Goedhals, Louis / Rapoport, Bernardo / Slabber, Coenraad F / Vorobiof, Daniel A

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde

    2003  Volume 93, Issue 10, Page(s) 728

    MeSH term(s) Education, Medical, Continuing/standards ; Humans ; Medical Oncology/education ; Medical Oncology/standards ; South Africa
    Language English
    Publishing date 2003-10
    Publishing country South Africa
    Document type Guideline ; Letter
    ZDB-ID 390968-2
    ISSN 2078-5135 ; 0256-9574 ; 0038-2469
    ISSN (online) 2078-5135
    ISSN 0256-9574 ; 0038-2469
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.406: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 645: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.

    Tyrrell, Christopher J / Payne, Heather / Tammela, Teuvo L J / Bakke, August / Lodding, Pär / Goedhals, Louis / Van Erps, Peter / Boon, Tom / Van De Beek, Cees / Andersson, Swen-Olof / Morris, Tom / Carroll, Kevin

    International journal of radiation oncology, biology, physics

    2004  Volume 60, Issue 2, Page(s) 476–483

    Abstract: Purpose: To evaluate the efficacy and tolerability of prophylactic breast irradiation in reducing the incidence and severity of bicalutamide-induced gynecomastia and breast pain.: Methods and materials: In all, 106 men with prostate cancer (T1b-T4/Nx/ ...

    Abstract Purpose: To evaluate the efficacy and tolerability of prophylactic breast irradiation in reducing the incidence and severity of bicalutamide-induced gynecomastia and breast pain.
    Methods and materials: In all, 106 men with prostate cancer (T1b-T4/Nx/M0) and no current gynecomastia/breast pain were enrolled in this randomized, sham-controlled, double-blind, parallel-group multicenter trial. Patients received either a single dose of electron beam radiotherapy (10 Gy) or sham radiotherapy. Bicalutamide (Casodex) 150 mg/day was administered for 12 months from the day of radiotherapy. Every 3 months, patients underwent physical examination and questioning about gynecomastia and breast pain.
    Results: The incidence of investigator-assessed gynecomastia was significantly lower with radiotherapy vs. sham radiotherapy (52% vs. 85%; odds ratio [OR], 0.13; 95% confidence interval [CI], 0.04, 0.38; p < 0.001); direct questioning showed similar results. Fewer radiotherapy patients had >/=5 cm gynecomastia (measured by calipers; 11.5% vs. 50.0% for sham radiotherapy), and fewer cases were moderate-to-severe in intensity (21% vs. 48%). Similar proportions of radiotherapy and sham radiotherapy patients experienced breast pain (83% vs. 91%; OR, 0.25; 95% CI, 0.05, 1.27; p = 0.221); patients receiving radiotherapy experienced some reduction in its severity (OR, 0.44; 95% CI, 0.20, 0.97; p = 0.0429).
    Conclusions: Prophylactic breast irradiation is an effective and well-tolerated strategy for prevention of bicalutamide-induced gynecomastia.
    MeSH term(s) Aged ; Aged, 80 and over ; Androgen Antagonists/adverse effects ; Anilides/adverse effects ; Breast/radiation effects ; Breast Diseases/chemically induced ; Breast Diseases/radiotherapy ; Confidence Intervals ; Double-Blind Method ; Electrons/therapeutic use ; Gynecomastia/chemically induced ; Gynecomastia/radiotherapy ; Humans ; Male ; Middle Aged ; Nitriles ; Pain/chemically induced ; Pain/radiotherapy ; Prostatic Neoplasms/therapy ; Tosyl Compounds
    Chemical Substances Androgen Antagonists ; Anilides ; Nitriles ; Tosyl Compounds ; bicalutamide (A0Z3NAU9DP)
    Language English
    Publishing date 2004-10-01
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2004.03.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1218: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.

    Lundström, Eija A / Rencken, Rupert K / van Wyk, Johann H / Coetzee, Lance J E / Bahlmann, Johann C M / Reif, Simon / Strasheim, Erdam A / Bigalke, Martin C / Pontin, Alan R / Goedhals, Louis / Steyn, Douw G / Heyns, Chris F / Aldera, Luigi A / Mackenzie, Thomas M / Purcea, Daniela / Grosgurin, Pierre Y / Porchet, Hervé C

    Clinical drug investigation

    2009  Volume 29, Issue 12, Page(s) 757–765

    Abstract: Background and objectives: Triptorelin 6-month formulation was developed to offer greater convenience to both patients and physicians by reducing the injection frequency. The efficacy, pharmacokinetics and safety of a new 6-month formulation of ... ...

    Abstract Background and objectives: Triptorelin 6-month formulation was developed to offer greater convenience to both patients and physicians by reducing the injection frequency. The efficacy, pharmacokinetics and safety of a new 6-month formulation of triptorelin were investigated over 12 months (48 weeks). The primary objective was to evaluate the formulation in achieving castrate serum testosterone levels (< or = 1.735 nmol/L or < or = 50 ng/dL) on day 29 and in maintaining castration at months 2-12. Absence of luteinizing hormone (LH) stimulation and change in prostate-specific antigen (PSA) level were also assessed.
    Methods: An open-label, non-comparative, phase III study in 120 patients with advanced prostate cancer was conducted from July 2006 to August 2007 in private and public institutions in South Africa. Each patient received two consecutive intramuscular injections of triptorelin embonate (pamoate) 22.5 mg at an interval of 24 weeks. In all patients, testosterone (primary outcome measurement) was measured at baseline and then every 4 weeks; LH was measured before and 2 hours after the two injections. PSA was measured on day 1 and at weeks 12, 24, 36 and 48. Adverse events were recorded at each visit.
    Results: In the intent-to-treat population, 97.5% (95% CI 92.9, 99.5) of patients achieved castrate serum testosterone levels by day 29, and 93.0% (95% CI 86.8, 97.0) maintained castration at months 2-12. After the second injection, 98.3% of patients showed absence of LH stimulation. The most frequent drug-related adverse events were hot flushes (71.7% of patients). No patient withdrew from the study as a result of an adverse event.
    Conclusions: The triptorelin 6-month formulation was well tolerated and was able to achieve and maintain castration for the treatment of locally advanced and metastatic prostate cancer. By reducing the frequency of required injections, this new formulation offers a more convenient treatment regimen. (Clinical Trial Registration,NCT00751790 at www.clinicaltrials.gov).
    MeSH term(s) Aged ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/adverse effects ; Antineoplastic Agents, Hormonal/pharmacokinetics ; Delayed-Action Preparations ; Hot Flashes/chemically induced ; Humans ; Injections, Intramuscular ; Male ; Middle Aged ; Neoplasm Metastasis ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology ; South Africa ; Testosterone/blood ; Triptorelin Pamoate/administration & dosage ; Triptorelin Pamoate/adverse effects ; Triptorelin Pamoate/pharmacokinetics
    Chemical Substances Antineoplastic Agents, Hormonal ; Delayed-Action Preparations ; Triptorelin Pamoate (08AN7WA2G0) ; Testosterone (3XMK78S47O) ; Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2009-07-16
    Publishing country New Zealand
    Document type Clinical Trial, Phase III ; Journal Article ; Multicenter Study
    ZDB-ID 1220136-4
    ISSN 1179-1918 ; 1173-2563 ; 0114-2402
    ISSN (online) 1179-1918
    ISSN 1173-2563 ; 0114-2402
    DOI 10.2165/11319690-000000000-00000
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2807: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top